Literature DB >> 2242008

R 76713 and enantiomers: selective, nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis.

H Vanden Bossche1, G Willemsens, I Roels, D Bellens, H Moereels, M C Coene, L Le Jeune, W Lauwers, P A Janssen.   

Abstract

The triazole derivative, R 76713 and its enantiomers R 83839(-) and R 83842(+) are effective inhibitors of the aromatization of androstenedione. For human placental microsomes, the (+) enantiomer (R 83824) is about 1.9- and 32-times more active than the racemate (IC50 2.6 nM) and the (-) enantiomer, respectively. R 83842 is about 30- and 1029-times more active than 4-hydroxyandrostene-3,17-dione and aminoglutethimide. This potency might originate from its high affinity for the microsomal cytochrome P450 (P450). Indeed, R 83842, compared to R 76713 and R 83839, forms a more stable P450-drug complex. Difference spectral measurements indicate that the triazole nitrogen N-4 coordinates to the haem iron. The reversed type 1 spectral changes suggest that R 76713 is able to displace the substrate from its binding place and the stable complex formed in particular with the (+) enantiomer suggests that its N-1-substituent occupies a lipophilic region of the apoprotein moiety. Kinetic analysis implies that there is a competitive part in the inhibition of the human placental aromatase by R 76713. The Ki values for R 76713, R 83842 and R 83839 are 1.3 nM, 0.7 nM and 18 nM, respectively. These results are indicative of stereospecificity for binding. Up to 10 microM, R 76713 and its enantiomers have no statistically significant effect on the regio- and stereoselective oxidations of testosterone in male rat liver microsomes. All three compounds have no effect on the P450-dependent cholesterol synthesis, cholesterol side-chain cleavage and 7 alpha-hydroxylation and 21-hydroxylase. At 10 microM, R 76713 has a slight effect on the bovine adrenal 11 beta-hydroxylase. This effect originates mainly from R 83839, the less potent aromatase inhibitor. On the other hand, the inhibition of the 17,20-lyase of rat testis observed at concentrations greater than or equal to 0.5 microM, originates rather from R 83842. However, 50% inhibition is only achieved at 1.8 microM R 83842, i.e. at a concentration about 1300-times higher than that needed to reach 50% inhibition of the human placental aromatase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242008     DOI: 10.1016/0006-2952(90)90346-m

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug.

Authors:  Kun-Eek Kil; Anat Biegon; Yu-Shin Ding; Andre Fischer; Richard A Ferrieri; Sung Won Kim; Deborah Pareto; Michael J Schueller; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2009-02       Impact factor: 2.408

2.  Unique distribution of aromatase in the human brain: in vivo studies with PET and [N-methyl-11C]vorozole.

Authors:  Anat Biegon; Sung Won Kim; David L Alexoff; Millard Jayne; Pauline Carter; Barbara Hubbard; Payton King; Jean Logan; Lisa Muench; Deborah Pareto; David Schlyer; Colleen Shea; Frank Telang; Gene-Jack Wang; Youwen Xu; Joanna S Fowler
Journal:  Synapse       Date:  2010-11       Impact factor: 2.562

Review 3.  Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.

Authors:  V C Njar; A M Brodie
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

4.  Kinetic and stereochemical studies on novel inactivators of C-terminal amidation.

Authors:  J Feng; J Shi; S R Sirimanne; C E Mounier-Lee; S W May
Journal:  Biochem J       Date:  2000-09-01       Impact factor: 3.857

5.  The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis.

Authors:  Hugo Vanden Bossche; Jannie Ausma; Hilde Bohets; Karen Vermuyten; Gustaaf Willemsens; Patrick Marichal; Lieven Meerpoel; Frank Odds; Marcel Borgers
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 6.  Aromatase inhibitors--mechanisms for non-steroidal inhibitors.

Authors:  H V Vanden Bossche; H Moereels; L M Koymans
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 7.  Vorozole, a specific non-steroidal aromatase inhibitor.

Authors:  W Wouters; E Snoeck; R De Coster
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 8.  In vivo visualization of aromatase in animals and humans.

Authors:  Anat Biegon
Journal:  Front Neuroendocrinol       Date:  2015-10-09       Impact factor: 8.606

Review 9.  Aromatase inhibitor development for treatment of breast cancer.

Authors:  S Masamura; H Adlercreutz; H Harvey; A Lipton; L M Demers; R J Santen; S J Santner
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

10.  Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates.

Authors:  Paul M Wood; L W Lawrence Woo; Mark P Thomas; Mary F Mahon; Atul Purohit; Barry V L Potter
Journal:  ChemMedChem       Date:  2011-05-23       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.